JPH0340032B2 - - Google Patents
Info
- Publication number
- JPH0340032B2 JPH0340032B2 JP9141182A JP9141182A JPH0340032B2 JP H0340032 B2 JPH0340032 B2 JP H0340032B2 JP 9141182 A JP9141182 A JP 9141182A JP 9141182 A JP9141182 A JP 9141182A JP H0340032 B2 JPH0340032 B2 JP H0340032B2
- Authority
- JP
- Japan
- Prior art keywords
- methylallantoin
- aluminum salt
- ppm
- ulcer
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 11
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 10
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 238000000862 absorption spectrum Methods 0.000 claims 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 230000003595 spectral effect Effects 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 description 5
- 229940015825 aldioxa Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9141182A JPS58208219A (ja) | 1982-05-31 | 1982-05-31 | ５−メチルアラントインアルミニウム塩およびそれを含有する消化性潰瘍治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9141182A JPS58208219A (ja) | 1982-05-31 | 1982-05-31 | ５−メチルアラントインアルミニウム塩およびそれを含有する消化性潰瘍治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58208219A JPS58208219A (ja) | 1983-12-03 |
| JPH0340032B2 true JPH0340032B2 (enrdf_load_stackoverflow) | 1991-06-17 |
Family
ID=14025631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9141182A Granted JPS58208219A (ja) | 1982-05-31 | 1982-05-31 | ５−メチルアラントインアルミニウム塩およびそれを含有する消化性潰瘍治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58208219A (enrdf_load_stackoverflow) |
-
1982
- 1982-05-31 JP JP9141182A patent/JPS58208219A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58208219A (ja) | 1983-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2203418B1 (en) | N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | |
| WO2012148252A2 (es) | Cocristales ionicos con base en metformina | |
| EP1844017A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| EP0047536A2 (en) | Substituted propylamines | |
| JPH09278655A (ja) | 非利尿性抗高血圧組成物 | |
| CN111925318B (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
| AU2019379797B2 (en) | Monohydrate potassium salt of a thienopyridone derivative and its preparation process | |
| CN108440456B (zh) | 奥利司他与有机酸钙的共晶体及包含该共晶体的药物组合物 | |
| US4098883A (en) | Aluminum compound and pharmaceutical compositions containing same | |
| JPH0340032B2 (enrdf_load_stackoverflow) | ||
| HU187626B (en) | Process for preparing vincamine saccharinate | |
| JP3356304B2 (ja) | 抗炎、抗潰瘍剤 | |
| JPS60501561A (ja) | アゾ−ビス−サリチル酸およびその塩、該酸および該塩の薬学的処方および使用、並びに該酸の製造 | |
| JPH0314036B2 (enrdf_load_stackoverflow) | ||
| JPS6281365A (ja) | グアニジノエタンチオスルホン酸、その製造法、及びそれを含有するコレステロ−ル低下剤 | |
| US3993778A (en) | Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use | |
| US3966960A (en) | 3-(4-Biphenylcarbonyl)propionic acid as an inhibitor of platelet aggregation | |
| KR20190090729A (ko) | 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| US3352751A (en) | Hexachlorophene derivatives for treating fascioliasis | |
| RU2034540C1 (ru) | Гипохолестеринемическое средство | |
| US4098887A (en) | Pharmaceutical compositions and methods of producing antiarthritic activity with bis(pyridine)gold(1+) salts | |
| US3956369A (en) | N-β-(2-acetyl-4-chlorophenoxy)-ethyl-N,N-dimethyl-N-benzyl-ammonium-p-chlorobenzene sulphonate, method for preparing same and medicinal preparation based thereon | |
| JPH0310607B2 (enrdf_load_stackoverflow) | ||
| US4156009A (en) | Diazepine derivatives | |
| EP0015684A1 (en) | Zinc aminophylline, its preparation and pharmaceutical use |